about tirzepatide
Tirzepatide compound is a once-weekly subcutaneous injectable peptide that activates receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake.

Tirzepatide is FDA approved under the brand name Zepbound™ for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity.

In clinical trials tirzepatide has been proven to be a very effective weight loss modality.

how does tirzepatide work?
Tirzepatide mimics the effect of “feeling full” resulting in decreased caloric intake. Delayed gastric emptying by reduction of glucagon secretion in a glucose-dependent manner. The effect of delay on gastric emptying can reduce appetite, improve control of eating and reduce food cravings.

A required full medical evaluation by a member of our healthcare team will be required. This evaluation will include laboratory testing, prior to initiating therapy, and again every three months.

Everyone will experience weight loss at different rates. In a comparison of the literature those individuals who took tirzepatide experienced weight loss as similar to semaglutide.